Reframing Immune-Mediated Inflammatory Diseases through Signature Cytokine Hubs
The New England Journal of Medicine:Rheumatoid Arthritis
by
3y ago
Immune-mediated inflammatory diseases (IMIDs) are a heterogeneous group of diseases characterized by chronic inflammation and organ damage. IMIDs were traditionally classified on the basis of the predominant organ involvement. Improving the pathogenic characterization of IMIDs, however, should ..read more
Visit website
Gastrointestinal Amyloidosis
The New England Journal of Medicine:Rheumatoid Arthritis
by
3y ago
Figure 1 ..read more
Visit website
Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
3y ago
Upadacitinib is an oral, reversible Janus kinase (JAK) inhibitor approved for the treatment of rheumatoid arthritis. Adalimumab is a tumor necrosis factor α inhibitor used to treat rheumatoid arthritis and psoriatic arthritis. In one trial involving patients with rheumatoid arthritis, upadacitinib ..read more
Visit website
Necrotizing Scleritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Figure 1 ..read more
Visit website
Fibroblasts in Rheumatoid Arthritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
The primary pathologic basis of rheumatoid arthritis resides in the synovium, a thin membrane lining the joint capsule. This membrane expands massively with the infiltration of immune and inflammatory cells. Drugs used in the treatment of rheumatoid arthritis suppress immune function, specifically ..read more
Visit website
Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Upadacitinib is an oral, reversible Janus kinase (JAK) inhibitor with selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2 that has been approved for the treatment of rheumatoid arthritis. Studies have shown remission with the use of upadacitinib in approximately 30% of patients regardless ..read more
Visit website
What Next after Biologic Therapy Fails in Rheumatoid Arthritis?
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Treatment of rheumatoid arthritis and other inflammatory joint diseases has been transformed by the use of biologic medicines. These targeted therapies are usually added to the treatment regimen when background conventional disease-modifying antirheumatic drugs (DMARDs) are insufficient. With these ..read more
Visit website
RNA Identification of PRIME Cells Predicting Rheumatoid Arthritis Flares
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Rheumatoid arthritis symptoms are highly dynamic, with periods of stability interrupted by unpredictable flares of disease activity. Such waxing and waning clinical courses are characteristic of many autoimmune diseases, including multiple sclerosis, systemic lupus erythematosus, and inflammatory ..read more
Visit website
PRIME Time in Rheumatoid Arthritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Rheumatoid arthritis, like many autoimmune diseases, has a course characterized by intermittent flares, yet our understanding of the mechanisms underlying flares remains limited. In an article published in this issue of the Journal, Orange and colleagues describe a study in which serial fingerstick ..read more
Visit website
Telescoping Fingers in Rheumatoid Arthritis
The New England Journal of Medicine:Rheumatoid Arthritis
by
4y ago
Figure 1 ..read more
Visit website

Follow The New England Journal of Medicine:Rheumatoid Arthritis on FeedSpot

Continue with Google
Continue with Apple
OR